BioCryst Pharmaceuticals Inc

BCRX

6.380USD

+0.140+2.24%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

BioCryst Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

5 / 392

Overall Ranking

77 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

BioCryst Pharmaceuticals Inc Highlights

StrengthsRisks

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with hereditary angioedema and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 66.42% year-on-year.

Undervalued

The company’s latest PE is -144.08, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 213.88M shares, increasing 6.83% quarter-over-quarter.

Held by John Hussman

Star Investor John Hussman holds 252.00K shares of this stock.

Analyst Rating

Based on 9 analysts

Buy

Current Rating

21.667

Target Price

+226.80%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of BioCryst Pharmaceuticals Inc is 8.77, ranking 33 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 159.40M, representing a year-over-year increase of 36.14%, while its net profit experienced a year-over-year increase of 191.92%.

Score

Industry at a Glance

Previous score

8.77

Change

0



Financials

6.09

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.78

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of BioCryst Pharmaceuticals Inc is 8.35, ranking 49 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -144.08, which is -97.31% below the recent high of -3.87 and -26.92% above the recent low of -182.87.

Score

Industry at a Glance

Previous score

8.35

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 5/392

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of BioCryst Pharmaceuticals Inc is 8.67, ranking 70 out of 392 in the Biotechnology & Medical Research industry. The average price target is 21.00, with a high of 30.00 and a low of 9.00.

Score

Industry at a Glance

Previous score

8.67

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of BioCryst Pharmaceuticals Inc is 6.47, ranking 198 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 7.44 and the support level at 5.63, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.47

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-05

The current institutional shareholding score of BioCryst Pharmaceuticals Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 103.62%, representing a quarter-over-quarter decrease of 2.11%. The largest institutional shareholder is The Vanguard, holding a total of 22.23M shares, representing 8.96% of shares outstanding, with 13.24% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

21.75M

+6.08%

BlackRock Institutional Trust Company, N.A.

16.91M

-0.72%

RA Capital Management, LP

15.30M

--

Deerfield Management Company, L.P.

12.17M

+159.36%

State Street Investment Management (US)

9.81M

+15.31%

Kynam Capital Management LP

9.39M

+10.95%

Two Sigma Investments, LP

8.66M

+1.69%

UBS Financial Services, Inc.

5.95M

+5.90%

Arrowstreet Capital, Limited Partnership

5.23M

+22.14%

Geode Capital Management, L.L.C.

5.05M

-0.05%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of BioCryst Pharmaceuticals Inc is 6.65, ranking 22 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.80. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. BioCryst Pharmaceuticals Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

BioCryst Pharmaceuticals Inc

BCRX

8.14 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.50 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.34 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ionis Pharmaceuticals Inc

IONS

8.30 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.12 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment